ReviewDrug design, development and therapy2026
Research Progress on the Application and Mechanisms of Baihe Dihuang Decoction in Major Depressive Disorder.
Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The treatment of major depressive disorder (MDD) is often plagued by inadequate therapeutic efficacy, high relapse rates, and adverse drug effects. Baihe Dihuang Decoction (BHDH, Lily Bulb and Rehmannia Decoction), a classic Traditional Chinese Medicine (TCM) formula, shows promise for depression, but a comprehensive synthesis of modern evidence is warranted. This study aimed to review the clinical efficacy, pharmacological mechanisms, and safety profile of BDD for MDD to inform its clinical application and guide future research. Methods: A systematic literature search was conducted in both English (PubMed, Web of Science) and Chinese (CNKI, Wanfang) databases from inception to June 2025. For clinical evidence, the search focused on "Baihe Dihuang Decoction", "major depressive disorder/depression", and "randomized controlled trial". Supplementary searches using terms like "chemical constituents" and "pharmacological action" were performed for mechanistic studies. Relevant literature was subsequently summarized and analyzed. Results: Current evidence suggests that BHDH, as an adjunct to conventional antidepressants, can improve the overall clinical response rate, reduce Hamilton Depression Rating Scale scores, and potentially alleviate adverse reactions. Its active constituents may exert antidepressant effects via multiple pathways, including monoaminergic neurotransmission modulation, neuroinflammation inhibition, hypothalamic-pituitary-adrenal axis regulation, hippocampal neuron protection, and gut microbiota modulation. However, its efficacy as a monotherapy and long-term safety profile require further validation through high-quality clinical trials. Conclusion: BHDH possesses a multi-target pharmacological basis for antidepressant activity. Existing clinical evidence supports its effectiveness and relative safety as an adjunctive therapy for MDD. To better define its clinical role and advance TCM modernization, future research should prioritize rigorous randomized controlled trials, elucidate its formula compatibility mechanisms, and identify its key bioactive components.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.